These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 33791846)

  • 1. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
    Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.
    Guy JB; Méry B; Ollier E; Espenel S; Vallard A; Wozny AS; Simonet S; Lauret A; Battiston-Montagne P; Ardail D; Alphonse G; Rancoule C; Rodriguez-Lafrasse C; Magné N
    Sci Rep; 2017 Sep; 7(1):12207. PubMed ID: 28939847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC).
    Moncharmont C; Guy JB; Wozny AS; Gilormini M; Battiston-Montagne P; Ardail D; Beuve M; Alphonse G; Simoëns X; Rancoule C; Rodriguez-Lafrasse C; Magné N
    Oncotarget; 2016 Jul; 7(30):47738-47749. PubMed ID: 27374096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 5. Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC.
    Gilormini M; Malesys C; Armandy E; Manas P; Guy JB; Magné N; Rodriguez-Lafrasse C; Ardail D
    Oncotarget; 2016 Mar; 7(13):16731-44. PubMed ID: 26934442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
    Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
    Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma.
    Keysar SB; Gomes N; Miller B; Jackson BC; Le PN; Morton JJ; Reisinger J; Chimed TS; Gomez KE; Nieto C; Frederick B; Pronk GJ; Somerset HL; Tan AC; Wang XJ; Raben D; Su TT; Jimeno A
    Cancer Res; 2020 Mar; 80(5):1183-1198. PubMed ID: 31911553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
    Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
    Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
    Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
    Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity.
    Li Y; Cui JT
    Biochem Biophys Res Commun; 2016 Sep; 477(4):607-613. PubMed ID: 27343560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.
    Driehuis E; Kolders S; Spelier S; Lõhmussaar K; Willems SM; Devriese LA; de Bree R; de Ruiter EJ; Korving J; Begthel H; van Es JH; Geurts V; He GW; van Jaarsveld RH; Oka R; Muraro MJ; Vivié J; Zandvliet MMJM; Hendrickx APA; Iakobachvili N; Sridevi P; Kranenburg O; van Boxtel R; Kops GJPL; Tuveson DA; Peters PJ; van Oudenaarden A; Clevers H
    Cancer Discov; 2019 Jul; 9(7):852-871. PubMed ID: 31053628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
    Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.